The American Cancer Society is proud to announce $43.2 million in funding for 92 new research grant awards to 69 institutions nationwide. These grants, awarded through the fall 2024 cycle, reflect our continued commitment to advancing cancer discovery and supporting researchers at every stage of their careers. Most new awards will begin on Sept. 1, or shortly thereafter.

The new funding slate spans eight standard grant mechanisms, including separate awards for Mentored Research Grants, Professorships, and Professor Renewals. This cycle features four new ACS Professors and five renewed Professorships, underscoring ACS’ investment in leadership and long-term impact in the cancer research community.

Also included are four awards totaling $1.58 million through the ACS IMPACT – Prostate Cancer Clinical Trials Expansion Grants (IMPACT-PCEGs). These awards, announced in response to a September 2024 request for applications, are designed to expand access to clinical trials and accelerate progress for patients with prostate cancer.

Areas of Impact

While many of the new projects address non-site-specific cancer topics, breast, prostate, and pancreatic cancers emerged as the most studied cancer types in this cycle, together accounting for nearly one-third of total funding (14%, 9%, and 9%, respectively). Importantly, these distributions reflect the strongest proposals received, as ACS does not prioritize funding by cancer type except when designated through specific RFAs.

Funding also spans the cancer continuum, with 41% supporting basic research, 21% focused on treatment, and 13% dedicated to improving cancer screening, detection, diagnosis, and prognosis. Together, these investments strengthen the foundation for future prevention, care, and survivorship breakthroughs.

The Power of Peer Review

This grant slate was made possible through the expertise and dedication of 637 volunteer reviewers across 21 peer review committees. Their careful evaluations ensure that ACS continues to fund the most innovative, impactful science.

Investing in the Future of Discovery

ACS remains committed to nurturing the next generation of cancer researchers while also recognizing established leaders. By supporting investigators across career stages, we help fuel discoveries that drive progress against cancer in all its forms. The fall 2024 slate reflects both the promise of early-career researchers and the enduring influence of senior leaders whose work is shaping the field.

To learn more, visit research news on cancer.org.​​